Improper use and discontinuation of anticoagulant therapy in a young male with a homozygous Factor V Leiden mutation led to 4 hospital admissions for recurrent venous thromboembolism over 5 years.
Case Report (n=1)
Patients with a homozygous Factor V Leiden mutation are at extremely high risk for recurrent venous thromboembolism and require early diagnosis, patient education, and potentially long-term uninterrupted anticoagulant therapy.
Venous thromboembolism (VTE), also known as deep vein thrombosis and pulmonary thromboembolism, is a medical condition that has a high incidence and a multifactorial pathogenesis. One of the causes is a mutation of the Factor V Leiden (FVL), which is the most common inherited thrombotic disorder. A mutation inherited from both parents is found in about 0.05-0.5% of cases, making our case more medically interesting. We presented the case of a young male patient with recurrent VTE and few risk factors who was admitted to the hospital 4 times with VTE symptoms over a 5-year period. In the background, there was a homozygous FVL mutation and improper use of anticoagulant therapy. We examined the medical data, diagnostics, therapy, and precautions that were and are required.
Šahinović et al. (Thu,) conducted a case report in Venous thromboembolism (n=1). Anticoagulant therapy was evaluated on Recurrent VTE. Improper use and discontinuation of anticoagulant therapy in a young male with a homozygous Factor V Leiden mutation led to 4 hospital admissions for recurrent venous thromboembolism over 5 years.